13th Euro Abstracts packets). The most widely kept medicines are medicines for the central nervous system (21%), the disorders in the digestive system and metabolism (16.7%) and medicines for the diseases of the respiratory system (14.5%). Nearly three-fourths of opened packets were not entirely consumed. a large number of medicines in home pharmacies (79%) was obtained self initiatedly and many of them were beyond their expiry date (9.5%). a total of 25% of the fi nancial means for those medicines was provided from health insurance funds. The total cost of medicines in home pharmacies per a family in Serbia was c25.13. a total of 72% of that amount was paid by the patients themselves. Pharmacoeconomic indicators in certain groups of medicines show that the largest percentage of the fi nancial means for home pharmacies in Serbia is spent on the medicines for gastrointestinal problems and metabolism disorders (17%). CONCLUSIONS: Based on the analyzed data, self-medication, that is, unreasonable use of medicines, is a big problem in Serbia. The use of these medicines involves the risk of inadequate treatment of the illness, frequent occurrence of side-effects which sometimes requires additional treatment, which only increases the expenses for both the patients and health funds. Therefore, it is necessary to closely monitor the issuing of prescriptions as well as educate the population.
PHP75 EVALUATION OF THE IMPACT OF INPATIENT CLINICAL PHARMACY SERVICES ON THE QUALITY AND COST OF PHARMACOTHERAPY IN INTERNAL MEDICINE WARDS
Pitakthum S Songkhla Hospital, Songkhla, Thailand OBJECTIVES: The purpose of this longitudinal descriptive study was to evaluate the infl uence of interventions by clinical pharmacists on processes, outcomes of care and economical outcomes. METHODS: The patients who were hospitalized at internal medicine wards, Songkhla hospital during October 1, 2008 -September 30, 2009 were recruited to this study. The core set of clinical pharmacy services were admission drug histories, drug protocol management, adverse drug reaction management, drug information, medical rounds and patient discharge counseling. The clinical pharmacists collected patients' data, pharmacists' interventions, direct drug cost-saving and activities on a specifi c designated form. The data was processed on a computerized database. Clinical pharmacist interventions were counted and classifi ed and analyzed to determine the infl uence on the quality and cost of pharmacotherapy. Descriptive statistics were used in data analysis. RESULTS: At the end of the study period the following were found: a total of 3796 patients were recruited. Clinical pharmacy services on internal medicine wards contribute to maximizing the pharmacotherapeutic effect and rationalization of drug therapy in 609 patients (16.0%), increase medication safety in 338 patients (8.9%) and reducing drug expenditures in 575 patients (15.1%). Costsaving from reconciling process was US$12,682 and cost-saving from pharmacists' interventions were US$6,298. The frequent type of interventions was maximizing the pharmacotherapeutic effect (40.8%), rationalization of drug therapy (30.3%) and minimizing the risk for developing adverse drug effects (28.9%), respectively. The top two of drug related problems found in cardiovascular drugs (30.5%) and antibiotic drugs (24.8%), respectively. CONCLUSIONS: The results of this study indicate that inpatient clinical pharmacy services on internal medicine wards contribute to rationalization of drug therapy, increase medication safety and reduced the direct expenditures on medications. Therefore, future studies should include multiple sites such as in a general surgical department and clinical pharmacy services should be continued.
PHP76 ALLOCATION OF A SINGLE BUDGET FOR HEALTH CARE, PROFESSIONAL EDUCATION, AND RESEARCH
Gandjour A Pennington Biomedical Research Center/Louisiana State University, Baton Rouge, LA, USA OBJECTIVES: Funding for health care programs competes with funding for professional education (ie, implementation of health care programs) and funding for research to reduce uncertainty around program cost-effectiveness. No study has yet shown how to allocate a combined budget for health care, professional education, and research. Previous work did not consider the fundamental idea that interventions with an acceptable incremental cost-effectiveness ratio (ICER) for an adoption decision may not be acceptable any more once implementation decisions are made simultaneously. Furthermore, previous work did not consider that cost-effectiveness of research is conditional upon the programs chosen for adoption and implementation. The purpose of this work is to present a sequential process to allocate a combined budget with the goal to maximize health. METHODS: Development of a 3-step allocation process to maximize health based on a single budget for health care, professional education, and research RESULTS: As a fi rst step, a league table approach determines which programs would be funded if the combined budget were spent just on adoption. The second step analytically determines a new (lower) threshold ICER which maximizes health by discontinuing programs above the new threshold and investing in implementing programs below the threshold. The third step considers cost-effectiveness of research to reduce uncertainty around program cost-effectiveness. In order to fund this research, the threshold ICER for adoption plus implementation has to be reduced further. In order to maximize health, ICERs of research studies need to equal the newly defi ned threshold ICER for adoption plus implementation. CONCLUSIONS: A 3-step allocation process is able to maximize health based on a single budget for health care, professional education, and research. Compared to a programming approach the proposed approach yields a closed-form analytical solution and is able to consider that research decisions are conditional upon adoption and implementation choices.
PHP77 DIRECT CONTRACTS ON PATENT-PROTECTED PHARMACEUTICALS IN GERMANY: MOTIVES OF SICK FUNDS AND PHARMACEUTICAL COMPANIES
Neurohr C, Huebner S, Ernst F, Welte R GlaxoSmithKline GmbH & Co. KG, Munich, Germany OBJECTIVES: To investigate the motives of both contracting parties, sick funds and pharmaceutical companies, to enter into direct contracts on patent-protected pharmaceuticals in the outpatient sector in Germany. METHODS: A systematic literature review was performed in March 2010 to identify contracts on patent-protected pharmaceuticals in Germany. Standard literature databases such as Pubmed and EMBASE, different market research databases and the 'Lauer-Taxe', the offi cial German price registry for pharmaceuticals were utilised. We included only offi cially reported contracts. a detailed market analysis was conducted to identify the motives of the identifi ed contracts. RESULTS: The number of direct contracts has been recently increasing. a total of 116 contracts were found. Formally, they are all rebate contracts due to German law. However, they include risk-sharing (n = 6), cost-sharing (2), added value (5) and simple rebate contracts (103). For sick funds, major motives were cost cutting, positioning within the market, attracting the "right" members, improving the medical treatment and right coding. Pharmaceutical companies show several motives that can be clustered into proactive and reactive motives: Proactive motives were: gaining access to reimbursement beyond standard coverage, funding of managed care concepts, bridging a time gap until market entry of a successor, maintaining the attractiveness after patent expiration as well as shaping the market access environment. Reactive motives were: rebate contracts of competitors, limitations and exclusions from reimbursement by the federal joint committee as well as reacting to attempts by sick funds and Associations of Statutory Health Insurance Physicians to control drug expenditures. CONCLUSIONS: Direct contracting on patent-protected pharmaceuticals seems to play a increasing role in the strategic considerations of pharmaceutical companies and sick funds. [NCPE] ). The objective of this study is to determine whether the likelihood of reimbursement in these markets is linked to HTA submission requirements. METHODS: Dossier requirements issued by NCPE, NICE, SMC and AWMSG were compared, and a checklist of requirements compiled. We investigated 20 interventions most recently reviewed by the NCPE, and recorded the recommendations for these compared with those issued by NICE, SMC and AWMSG. RESULTS: Economic analysis is key for an NCPE submission, although there are no specifi c requirements or template for the clinical data. Requirements for NICE are the most stringent; SMC and AWMSG have similar requirements. Of 20 interventions reviewed by NCPE, 11 (55%) were reimbursed
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